Mankind Pharma has announced a strategic collaboration with Denovo Sciences to strengthen its drug discovery capabilities through artificial intelligence (AI), marking a significant step toward technology-enabled pharmaceutical research. The partnership aims to accelerate the identification of promising drug candidates while reducing the time and cost associated with early-stage drug development.
Under the collaboration, Mankind Pharma will combine its research and development expertise, clinical development capabilities, and experimental validation infrastructure with Denovo Sciences’ proprietary AI-powered molecular generation and prioritization platform. The integrated approach is expected to improve the quality of lead candidates and enable researchers to identify high-potential molecules more efficiently.
A key feature of the collaboration is the adoption of a human-in-the-loop model, where artificial intelligence generates and evaluates potential molecular candidates while experienced scientists validate, refine, and guide the decision-making process. This hybrid approach is designed to maintain scientific rigor while leveraging AI to explore a broader range of molecular possibilities.
According to Mankind Pharma, the initiative focuses on three primary objectives: reducing early drug discovery timelines, enhancing the quality of lead compounds, and ensuring that only the most promising candidates advance into further development. By applying computational precision during the initial stages of research, both organizations aim to minimize resources spent on molecules with lower chances of success.
The collaboration reflects the growing adoption of AI technologies within the pharmaceutical industry, where advanced computational tools are increasingly being used to improve research productivity and accelerate the development of innovative therapies. Faster and more precise drug discovery could ultimately help bring effective and affordable medicines to patients sooner.
